Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin for acute irritative urinary toxicity during prostate radiotherapy
2014-004296-22Phase 3Terminated
- Sponsor
- Centre Eugène Marquis
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of solifenacin in Micturition disorder, Urotoxicity and prostate cancer (PCa), sponsored by Centre Eugène Marquis. Primary endpoint: Change in irritative urinary symptomatology during prostate irradiation. Started Dec 2015; status: terminated.
02
Drugs
solifenacin
03
Conditions
Micturition disorderUrotoxicityprostate cancer (PCa)
Beyond the preview
Go deeper on 2014-004296-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004296-22.